Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT

INCLUSION CRITERIA

Acute myelogenous leukemia (AML), beyond 2nd remission or relapsed/refractory disease, age 2 to 60 years
AML, in first or subsequent remission or relapsed/refractory disease, age 51 to 60 years of age
AML with multilineage dysplasia
Acute lymphoblastic leukemia (ALL), beyond 2nd remission or relapsed/refractory disease, age 2 to 60 years
ALL, age 51 - 60 years in first or subsequent remission or relapsed/refractory disease
Chronic myeloid leukemia (CML), beyond 2nd chronic phase or in blast crisis
Myelodysplastic syndrome (MDS), including World Health Organization (WHO)classifications of refractory anemia with excess blasts-1 (RAEB-1), RAEB-2 and therapy-related MDS
MDS with poor long-term survival including myeloid metaplasia and myelofibrosis
Myeloproliferative disorders
High-risk non-Hodgkin lymphoma (NHL) in 1st emission
Relapsed or refractory NHL
Hodgkin lymphoma (HL) beyond first remission
Males and females of any ethnic background, 2 to 60 years of age
Karnofsky Performance Status (KPS) ≥ 70% or Lansky performance status > 70% for patients < 16 years of age.
Related, matched-donor identified [6/6 human leukocyte antigen (HLA)-A, B and DRB1]
Willingness to take oral medications during the transplantation period
Ability to understand and the willingness to sign a written informed consent document

EXCLUSION CRITERIA

Prior myeloablative allogeneic or autologous hematopoietic stem cell transplant (HSCT)
HIV infection
Pregnant
Lactating
Evidence of uncontrolled active infection
Serum creatinine > 1.5 mg/dL or 24-hour creatinine clearance < 50 mL/min
Direct bilirubin, Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2 x upper limit of normal (ULN)
Carbon monoxide diffusing capacity (DlCO) < 60% predicted (adults) OR and in-room air oxygen saturation < 92% (children)
Left ventricular ejection fraction < 45% (adults) OR shortening fraction < 26%(children)
Fasting cholesterol > 300 mg/dL or Triglycerides > 300 mg/dL while on lipid-lowering agents.
Receiving investigational drugs unless cleared by the Principal Investigator (PI).
Prior malignancies except basal cell carcinoma or treated carcinoma in-situ.
Cancer treated with curative intent ≤ 5 years (EXCEPTION BY PI DISCRETION) (Cancer treated with curative intent > 5 years will be allowed).